In this Issue:
Alectinib active in crizotinib-resistant ALK-rearranged NSCLC
Real-world bevacizumab data in NSCLC
Ramucirumab + docetaxel in second-line setting
Nondisruptive p53 mutations linked to shorter survival
Evaluating HER2
overexpression, amplification and mutations
Mutation screening in cfDNA from lung cancer patients
Using ctDNA to detect EGFR mutation status
Adjunctive obatoclax mesylate in extensive-stage SCLC
Prevalence of VTE in newly diagnosed lung cancer
Treating major depression in lung cancer
Please login below to download this issue (PDF)